Royalty Pharma Reports Q4 and Full Year 2024 Results
Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...
The Lancet21h
Breaking the silence: MASLD and the scarcity of data on the Roma population
Non-communicable diseases rank among the most serious global health challenges of the 21st century due to their high prevalence and substantial socioeconomic and health-care impact. According to WHO, ...